高端疫苗 (6547.TW) 2025Q4 financial report shows revenue of 147.01M TWD, with a YoY growth rate of 14.14%. This figure indicates that 高端疫苗 (6547.TW)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of 高端疫苗 (6547.TW)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.
6547
高端疫苗
2.74%
(0.03)